RU2641693C2 - Соединения 5-(пиридин-2-иламино)-пиразин-2-карбонитрила и их терапевтическое применение - Google Patents

Соединения 5-(пиридин-2-иламино)-пиразин-2-карбонитрила и их терапевтическое применение Download PDF

Info

Publication number
RU2641693C2
RU2641693C2 RU2014121334A RU2014121334A RU2641693C2 RU 2641693 C2 RU2641693 C2 RU 2641693C2 RU 2014121334 A RU2014121334 A RU 2014121334A RU 2014121334 A RU2014121334 A RU 2014121334A RU 2641693 C2 RU2641693 C2 RU 2641693C2
Authority
RU
Russia
Prior art keywords
compound
compound according
cancer
treatment
rars
Prior art date
Application number
RU2014121334A
Other languages
English (en)
Russian (ru)
Other versions
RU2014121334A (ru
Inventor
Ян КОЛЛИНС
Майкл ЛЭЙНЧБАРИ
Томас Питер МЭТТЬЮС
Джон Чарльз РИДЕР
Original Assignee
Кансер Ресёрч Текнолоджи Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Кансер Ресёрч Текнолоджи Лимитед filed Critical Кансер Ресёрч Текнолоджи Лимитед
Publication of RU2014121334A publication Critical patent/RU2014121334A/ru
Application granted granted Critical
Publication of RU2641693C2 publication Critical patent/RU2641693C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2014121334A 2011-11-09 2012-11-09 Соединения 5-(пиридин-2-иламино)-пиразин-2-карбонитрила и их терапевтическое применение RU2641693C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161557457P 2011-11-09 2011-11-09
US61/557,457 2011-11-09
PCT/GB2012/052786 WO2013068755A1 (en) 2011-11-09 2012-11-09 5-(pyridin-2-yl-amino)-pyrazine-2-carbonitrile compounds and their therapeutic use

Publications (2)

Publication Number Publication Date
RU2014121334A RU2014121334A (ru) 2015-12-20
RU2641693C2 true RU2641693C2 (ru) 2018-01-22

Family

ID=47178213

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2014121334A RU2641693C2 (ru) 2011-11-09 2012-11-09 Соединения 5-(пиридин-2-иламино)-пиразин-2-карбонитрила и их терапевтическое применение

Country Status (10)

Country Link
US (3) US9040540B2 (https=)
EP (1) EP2776417B1 (https=)
JP (1) JP6073910B2 (https=)
CN (1) CN104105696B (https=)
AU (1) AU2012335409B2 (https=)
BR (1) BR112014010938A2 (https=)
CA (1) CA2849566C (https=)
ES (1) ES2709003T3 (https=)
RU (1) RU2641693C2 (https=)
WO (1) WO2013068755A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2641693C2 (ru) 2011-11-09 2018-01-22 Кансер Ресёрч Текнолоджи Лимитед Соединения 5-(пиридин-2-иламино)-пиразин-2-карбонитрила и их терапевтическое применение
RU2659786C2 (ru) 2012-05-15 2018-07-04 Кансер Ресёрч Текнолоджи Лимитед 5-[[4-[[морфолин-2-ил]метиламино]-5-(трифторметил)-2-пиридил]амино]пиразин-2-карбонитрил, его терапевтические применения
CZ306322B6 (cs) 2014-12-17 2016-11-30 Univerzita Karlova v Praze, Farmaceutická fakulta v Hradci Králové Substituovaný 2-(2-fenylhydrazinyl)pyrazin, způsob jeho přípravy, jeho použití a farmaceutický přípravek ho obsahující
TW202340194A (zh) 2017-02-16 2023-10-16 美商基利科學股份有限公司 吡咯并[1,2-b]嗒𠯤衍生物
TWI842978B (zh) 2018-07-13 2024-05-21 美商基利科學股份有限公司 衍生物
CN110872277B (zh) * 2019-11-14 2021-06-04 浙江大学 N-取代芳环-2-氨基嘧啶类化合物及用途
TW202204348A (zh) 2020-04-07 2022-02-01 美商西爾拉癌症醫學公司 Ｃｈｋ１抑制劑之合成方法
JP2024511277A (ja) 2021-02-19 2024-03-13 メビオン・メディカル・システムズ・インコーポレーテッド 粒子線治療システムのためのガントリー

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200800441A1 (ru) * 2005-08-30 2008-08-29 Новартис Аг Замещенные бензимидазолы в качестве ингибиторов киназ
WO2009044162A1 (en) * 2007-10-05 2009-04-09 Cancer Research Technology Limited Pyrazin-2-yl-pyridin-2-yl-amine and pyrazin-2-yl-pyrimidin-4-yl-amine compounds and their use
WO2009103966A1 (en) * 2008-02-19 2009-08-27 Cancer Research Technology Limited Bicyclylaryl-aryl-amine compounds and their use

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773778A (en) 1972-01-24 1973-11-20 Squibb & Sons Inc Sulfur derivatives of pyrazolo (3,4-b)pyridines
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
MX9800215A (es) 1995-07-06 1998-03-31 Novartis Ag Pirrolopirimidas y procesos para su preparacion.
EP1435947B1 (en) 2001-10-19 2007-08-15 Ortho-McNeil Pharmaceutical, Inc. 2-phenyl benzimidazoles and imidazo-¬4,5|-pyridines as cds1/chk2-inhibitors and adjuvants to chemotherapy or radiation therapy in the treatment of cancer
JP5039268B2 (ja) 2001-10-26 2012-10-03 アベンティス・ファーマスーティカルズ・インコーポレイテツド ベンゾイミダゾールおよび類縁体および蛋白キナーゼ阻害剤としてのその使用
EP1442039A1 (en) 2001-10-31 2004-08-04 Bayer HealthCare AG Pyrimido (4,5-b) indole derivatives
EP1501514B1 (en) 2002-05-03 2012-12-19 Exelixis, Inc. Protein kinase modulators and methods of use
US7202244B2 (en) 2002-05-29 2007-04-10 Millennium Pharmaceuticals, Inc. Chk-1 inhibitors
MXPA06001098A (es) 2003-07-29 2006-04-24 Irm Llc Compuestos y composiciones utiles como inhibidores de proteina cinasa.
AU2004279427B2 (en) 2003-10-08 2008-07-03 Irm Llc Compounds and compositions as protein kinase inhibitors
AU2004282179B2 (en) 2003-10-14 2011-05-19 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein kinase inhibitors
CN1882345A (zh) 2003-10-16 2006-12-20 希龙公司 作为raf激酶抑制剂以治疗癌症的2,6－二取代的喹唑啉、喹喔啉、喹啉和异喹啉
US7163939B2 (en) 2003-11-05 2007-01-16 Abbott Laboratories Macrocyclic kinase inhibitors
US20050096324A1 (en) 2003-11-05 2005-05-05 Zhi-Fu Tao Macrocyclic kinase inhibitors
ATE458730T1 (de) 2004-04-13 2010-03-15 Icagen Inc Polycyclische pyrazine als kaliumionenkanal- modulatoren
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
US20090029982A1 (en) 2005-04-28 2009-01-29 Supergen, Inc. Protein kinase inhibitors
NZ565040A (en) 2005-06-28 2010-05-28 Sanofi Aventis Isoquinoline derivatives as inhibitors of RHO-kinase
CN101321760A (zh) 2005-10-06 2008-12-10 先灵公司 作为蛋白激酶抑制剂的吡唑并嘧啶
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
KR20090092303A (ko) 2006-12-27 2009-08-31 사노피-아벤티스 사이클로알킬아민 치환된 이소퀴놀린 유도체
DK2134689T3 (da) 2007-03-16 2014-06-30 Scripps Research Inst Inhibitorer af fokal adhæsionskinase
WO2008117050A1 (en) 2007-03-27 2008-10-02 Astrazeneca Ab Pyrazolyl-amino-substituted pyrazines and their use for the treatment of cancer
EP2170886A1 (en) 2007-07-02 2010-04-07 Cancer Research Technology Limited 9h-pyrimido[4,5-b]indoles, 9h-pyrido[4',3':4,5]pyrrolo[2,3-d]pyridines, and 9h-1,3,6,9-tetraaza-fluorenes as chk1 kinase function inhibitors
CA2725754C (en) * 2008-06-11 2017-05-23 Hazel Joan Dyke Diazacarbazoles and methods of use
RU2641693C2 (ru) 2011-11-09 2018-01-22 Кансер Ресёрч Текнолоджи Лимитед Соединения 5-(пиридин-2-иламино)-пиразин-2-карбонитрила и их терапевтическое применение
RU2659786C2 (ru) 2012-05-15 2018-07-04 Кансер Ресёрч Текнолоджи Лимитед 5-[[4-[[морфолин-2-ил]метиламино]-5-(трифторметил)-2-пиридил]амино]пиразин-2-карбонитрил, его терапевтические применения

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200800441A1 (ru) * 2005-08-30 2008-08-29 Новартис Аг Замещенные бензимидазолы в качестве ингибиторов киназ
WO2009044162A1 (en) * 2007-10-05 2009-04-09 Cancer Research Technology Limited Pyrazin-2-yl-pyridin-2-yl-amine and pyrazin-2-yl-pyrimidin-4-yl-amine compounds and their use
WO2009103966A1 (en) * 2008-02-19 2009-08-27 Cancer Research Technology Limited Bicyclylaryl-aryl-amine compounds and their use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Michael Lainchbury; Ian Collins, Checkpoint kinase inhibitors: a patent review, EXPERT OPINION ON THERAPEUTIC PATENTS, 2011, 21, N 8, стр. 1191 - 1210. *

Also Published As

Publication number Publication date
US9765059B2 (en) 2017-09-19
US20160304493A1 (en) 2016-10-20
JP2014532751A (ja) 2014-12-08
CA2849566C (en) 2021-02-09
US9403797B2 (en) 2016-08-02
EP2776417A1 (en) 2014-09-17
CA2849566A1 (en) 2013-05-16
JP6073910B2 (ja) 2017-02-01
AU2012335409A1 (en) 2014-04-17
US20150225372A1 (en) 2015-08-13
CN104105696B (zh) 2017-11-14
WO2013068755A1 (en) 2013-05-16
BR112014010938A2 (pt) 2017-05-16
EP2776417B1 (en) 2018-10-31
AU2012335409B2 (en) 2017-07-13
RU2014121334A (ru) 2015-12-20
US20140315925A1 (en) 2014-10-23
ES2709003T3 (es) 2019-04-12
CN104105696A (zh) 2014-10-15
US9040540B2 (en) 2015-05-26

Similar Documents

Publication Publication Date Title
RU2659786C2 (ru) 5-[[4-[[морфолин-2-ил]метиламино]-5-(трифторметил)-2-пиридил]амино]пиразин-2-карбонитрил, его терапевтические применения
RU2641693C2 (ru) Соединения 5-(пиридин-2-иламино)-пиразин-2-карбонитрила и их терапевтическое применение
CN113490495B (zh) Helios的小分子降解剂及其使用方法
JP6869947B2 (ja) 置換キナゾリン化合物ならびにそのｇ１２ｃ変異ｋｒａｓ、ｈｒａｓおよび／またはｎｒａｓタンパク質の阻害剤としての使用
WO2020125513A1 (zh) 作为cdk抑制剂的大环化合物、其制备方法及其在医药上的应用
CN104945401B (zh) Ip化合物及它们在治疗中的应用
CN114057771B (zh) 大环化合物及其制备方法和应用
US20070049603A1 (en) Raf inhibitor compounds and methods of use thereof
JP2018150316A (ja) 化合物およびその使用方法
JP2008530011A (ja) Ｒａｆインヒビター化合物および方法
TW202124381A (zh) 咪唑並[4,5-c]喹啉-2-酮化合物及它們在治療癌症中之用途
JP2020520960A (ja) アザアリール誘導体、その製造方法および薬学上の応用
US10501466B2 (en) WDR5 inhibitors and modulators
JP2023545588A (ja) ヘテロ環式カリンｒｉｎｇユビキチンリガーゼ化合物及びその使用
KR20190129923A (ko) 듀테로화된 이미다조[4,5-c]퀴놀린-2-온 화합물 및 암 치료시 이들의 용도
CN107686477A (zh) 作为cdk4/6抑制剂的新型化合物及其应用
HK1198365A1 (en) Imidazopyridine compounds, compositions and methods of use
TW201902892A (zh) 化合物
KR20110015627A (ko) 치환된 피롤 및 사용 방법
CN120435458A (zh) 取代的喹啉作为改进的nf-kb诱导激酶(nik)抑制剂
HK1254606B (zh) 手性二芳基大环及其用途
HK1174038A (en) 1h-pyrazolo [ 3, 4-b] pyridine compounds for inhibiting raf kinase